Drugs / NK Cell enriched-DLI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02452697 Comparator | Jun 2016 → Jul 2022 | lymphoid neoplasm, myeloid neoplasm | Cristina Gasparetto | Unknown | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK Cell enriched-DLI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452697 ↗ |
| Modality | Cell therapy | “The donor NK cells will be infused over 30 minutes intravenously.” NCT02452697 ↗ |
| Route | Intravenous | “The donor NK cells will be infused over 30 minutes intravenously.” NCT02452697 ↗ |